Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD) with a $36.00 price target, while shares closed at $27.15. The broader market consensus is a Moderate Buy with an average target of $33.21. Additionally, H.C. Wainwright maintained a Buy rating with a $37.00 target in a July 30 report.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on ACADIA Pharmaceuticals yesterday and set a price target of $36.00. The company’s shares closed yesterday at $27.15.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Arcutis Biotherapeutics, and ACADIA Pharmaceuticals. According to TipRanks, Ear has an average return of 5.7% and a 42.38% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $33.21 average price target, implying a 22.32% upside from current levels. In a report released on July 30, H.C. Wainwright also maintained a Buy rating on the stock with a $37.00 price target.